JANSSEN PHARMACEUTIC v. MYLAN PHARMACEUTICAL
2:03-cv-06220
Overview
Parties
Defendant
MYLAN PHARMACEUTICALS INC. Operating Company
Represented By
2 Attorneys ListedSAIBER LLC
SAIBER LLC, ONE GATEWAY CENTER
SAIBER LLC
SAIBER LLC, ONE GATEWAY CENTER
Plaintiff
JANSSEN PHARMACEUTICA N.V. NPE (Individual / Inventor)
Represented By
5 Attorneys ListedLOWENSTEIN SANDLER PC
65 LIVINGSTON AVENUE, ROSELAND, NJ 07068-1791
KIRKPATRICK & LOCKHART PRESTON GATES ELLIS
KIRKPATRICK & LOCKHART PRESTON GATES ELLIS, ONE NEWARK CENTER
LOWENSTEIN SANDLER
LOWENSTEIN SANDLER, 65 LIVINGSTON AVENUE
LOWENSTEIN SANDLER, PC
65 LIVINGSTON AVENUE, ROSELAND, NJ 07068
BUCKALEW FRIZZELL & CREVINA LLP
116 VILLAGE BOULEVARD, SUITE 200
JANSSEN PHARMACEUTICA PRODUCTS, L.P. Operating Company
Represented By
5 Attorneys ListedLOWENSTEIN SANDLER PC
65 LIVINGSTON AVENUE, ROSELAND, NJ 07068-1791
KIRKPATRICK & LOCKHART PRESTON GATES ELLIS
KIRKPATRICK & LOCKHART PRESTON GATES ELLIS, ONE NEWARK CENTER
LOWENSTEIN SANDLER
LOWENSTEIN SANDLER, 65 LIVINGSTON AVENUE
LOWENSTEIN SANDLER, PC
65 LIVINGSTON AVENUE, ROSELAND, NJ 07068
BUCKALEW FRIZZELL & CREVINA LLP
116 VILLAGE BOULEVARD, SUITE 200
Court & Judges
Court
District Court, D. New Jersey (njd)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360Β° Radar 2 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| πΊπΈ United States | US 4,804,663 A Asserted | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 71,706,785 A | US Continuation / Sibling | View Official Patent → |
JANSSEN PHARMACEUTICAL, N.V. v. APOTEX, INC.
Patents Involved
There is a single patent involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US4804663
3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
|
Filed: 1986-02-05
Issued: 1989-02-14
|
Expired (Term Ended)
+692d PTA
Expires: 2007-12-29
|
Patent Enforceability & Injunction Risk Assessment
Statutorily Barred β Patent expired. Under 35 U.S.C. Β§ 283, courts cannot grant an injunction once a patent's term concludes. Litigation is restricted exclusively to past damages lookback.
High PTA (+692 days) / Cellect Scrutiny β Over 692 days of PTA awarded. Susceptible to In re Cellect double patenting invalidation if continuation patents in the same family expire earlier.
Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).
Procedural Motions & Interlocutory Orders
Total Motions
20
Dispositive
18
Granted
0
Denied
0
Pending / Review
20
Motions by Category
Key Dispositive Motions & Rulings